Pfizer Inc (PFE): Xtandi phase-3 shows statsig-superior MF...

Reply Private New

Replies (1) Next 10 Prev Next

Send PM Follow Ignore

Followers	826
Posts	119569
Boards Moderated	14
Alias Born	09/05/2002

DewDiligence

Re: DewDiligence post# 5021

Thursday, 03/16/2023 8:24:42 PM

Thursday, March 16, 2023 8:24:42 PM

Xtandi phase-3 shows statsig-superior MFS* both as an addend to Lupron (compared to Lupron alone) and as monotherapy compared to Lupron in non-metastatic HSPC patients at high-risk for disease recurrence:

https://www.pfizer.com/news/press-release/press-release-detail/phase-3-study-shows-xtandir-enzalutamide-plus-leuprolide

The (secondary endpoint) OS data are not yet mature, but are trending positively for Xtandi + Lupron vs Lupron alone. The full dataset will be presented at an unspecified medical conference.

PFE booked $1.2B in Xtandi-alliance revenue in 2022 pursuant to its worldwide collaboration with Astellas that splits US profits 50/50 and pays PFE royalties on ex-US sales. Xtandi goes off-patent in the US in 2027.

*Metastasis-free survival (similar to PFS).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”